Present status and perspectives in the treatment of hormone-refractory prostate cancer

Oncology

Volumn 69, Issue 4, 2005, Pages 273-282

  Silvestris, Nicola ^a   Leone, Bernardo ^d   Numico, Gianmauro ^b   Lorusso, Vito ^c   De Lena, Mario ^c  

^a Operative Unit of Medical Oncology   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d Grupo Oncologico Cooperativo del Sur   (Argentina)

Author keywords

Androgen deprivation; Chemotherapy; Hormone refractory cancer; Prostate cancer; Radiotherapy

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLUTETHIMIDE; ANTICOAGULANT AGENT; BEVACIZUMAB; CALCITRIOL; CLODRONIC ACID; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ESTRAMUSTINE PHOSPHATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PAMIDRONIC ACID; PREDNISONE; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SURAMIN; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; ZOLEDRONIC ACID;

BONE MARROW TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; HEART DISEASE; HUMAN; METABOLIC DISORDER; NEUROLOGIC DISEASE; NEUTROPENIA; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHINITIS; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOEMBOLISM;

ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 28644444288     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089676     Document Type: Review

References (77)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Scherr D, Swindle PW, Scardino PT: National Comprehensive Cancer Network guidelines for the management of prostate cancer (review). Urology 2003;61(suppl 2A):14-24.
3. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-1490.
4. Scher HI, Mazumdar M, Kelly NK: Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 1996;88:1623-1634.
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
6. Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996;14:5137-5142.
7. Ferro MA, Gillatt D, Symes MO, Smith PJ: High-dose intravenous estrogen therapy in advanced prostatic carcinoma: use of serum prostate-specific antigen to monitor response. Urology 1989;34:134-138.
8. Smith DC, Dunn RL, Strawdeman MS, Pienta KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835-1843.
9. Scher HI, Kelly WK, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999;91:244-251.
10. Morris MJ, Scher HI: Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. Crit Rev Oncol Hematol 2003;46:821-831.
11. Walsh P, Worthington J (eds): The Prostate. Baltimore, Johns Hopkins University Press, 1995.
12. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin Oncol 1985;3:827-841.
13. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(suppl 3):1089-1109.
14. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-1764.
15. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ: Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukaemia Group B 9182 study. J Clin Oncol 1999;17:2506-2513.
16. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
17. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
18. Fowler JE, Whitmore WF: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126:372-375.
19. Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11:2167-2172.
20. Hussain M, Wolf M, Marshall M, Crawford ED, Eisenberger M: Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994;12:1868-1875.
21. Chao D, Harland SJ: The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. Eur Urol 1997;31:7-10.
22. Osoba D, Tannock IF, Ernst DS, Neville AJ: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1854-1863.
23. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985;69:885-886.
24. Abratt RP, Brune D, Meletis-Athanassios D, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T, Oudard S: Randomized phase III study of i.v. vinorelbine plus hormonotherapy versus hormonotherapy alone in hormone-refractory prostate cancer. Ann Oncol 2004;15:1613-1621.
25. Perry CA, McTavish D: Estramustine phosphate disodium: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995;7:149-174.
26. Martel CL, Gumerlock PH, Meyers FJ, Lara PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171-187.
27. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999;17:3160-3166.
28. Ganansia-Leymarie V, Bishoff P, Bergerat JP, et al: Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-Cancer Agents 2003;3:291-306.
29. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ: Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72:2457-2460.
30. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, Hussain M: Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000;89:431-436.
31. Beer TM, Pierce WC, Lowe BA, Henner WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-1279.
32. Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28(4 suppl 15):8-15.
33. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, Camerlo J, Genre D, Bardou VJ, Maraninchi D, Viens P: Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003;98:1627-1634.
34. Beer T, Berry W, Wersinger EM, Bland LB: Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003;2:167-172.
35. Hudes GR, Manola J, Conroy J, Habermann T, Wilding G: Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group (abstract 697). Proc Am Soc Clin Oncol 2001;20:175.
36. Berry W, Grengurich M, Dakhil S, Hathorn J, Asmar L: Phase II randomized study of weekly paclitaxel (Taxol®) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (abstract 696). Proc Am Soc Clin Oncol 2001;20:175.
37. Petrylak D, Shelton G, England-Owen C, Pfaff C, Bagliella E, Diuleo R, Katz A, Zuech N, Sawczuk I, Benson M, Olsson C: Response and preliminary survival results of a phase II study of docetaxel and estramustine in patients with androgen-independent prostate cancer (abstract 1312). Proc Am Soc Clin Oncol 2000;19:334.
38. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ: Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509-2516.
39. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002;94:1457-1465.
40. Weitzman AL, Shelton G, Zeuch N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, Pfaff C, Newhouse JH, Petrylak DP: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000;163:834-837.
41. Higano CS, Ellis W, Russel K, Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48:600-604.
42. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM: Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003;89:968-970.
43. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2451-2453.
44. Gulley JL, Dahut WL: Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patients. Urology 2003;62(suppl 6B):147-154.
45. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev 2002;2:584-593.
46. Saad F, Schulman CC: Role of biphosphonates in prostate cancer. Eur Urol 2004;45:26-34.
47. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: Zoledronic Acid Prostate Cancer Study Group: a randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
48. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-4284.
49. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3333-3342.
50. Morris MJ, Scher HI: Clinical approaches to osseous metastases in prostate cancer. Oncologist 2003;8:161-173.
51. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001;357:336-341.
52. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, FiggWD: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:1738-1744.
53. Celluzzi C, Mayordomo J, Storkaus W, Lotze MT, Falo LD: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
54. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;23:3894-3903.
55. Small EJ, Rini B, Higano C, Redfern C, Nemunaitis J, Valone F, Kylstra J, Schellhammer PF: A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (abstract 1534). Proc Am Soc Clin Oncol 2003;22:382.
56. Klasa RJ, Gillum AM, Klem RE, Frankel SR: Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
57. Chi KN, Murray RN, Gleave ME, Kuhn J, Izbicka E, Berg K, Rowinsky EK, Tolcher AW: A phase II study of oblimersen disodium and docetaxel in patients with metastatic hormone-refractory prostate cancer (abstract 1580). Proc Am Soc Clin Oncol 2003;22:393.
58. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440-1450.
59. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ: Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. J Clin Oncol 2002;20:3369-3375.
60. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25.
61. Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, Bettencourt LA, Zhang MH, Clendeninn NJ, Wilding G: Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (abstract 692). Proc Am Soc Clin Oncol 2001;20:174b.
62. Lassiter LK, Carducci MA: Endothelial receptor antagonists in the treatment of prostate cancer. Semin Oncol 2003;30:678-688.
63. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-689.
64. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
65. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-2539.
66. Salimichokami M: Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer, a randomized study of weekly docetaxel alone or in combination with thalidomide (abstract 1725). Proc Am Soc Clin Oncol 2003;22:429.
67. Picus J, Halabi S, Rini B, Vogelzang N, Whang Y, Kaplan E, Kelly W, Small E: The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006 (abstract 1578). Proc Am Soc Clin Oncol 2003;22:393.
68. Miller K, Raabe N, Trachtenberg J, et al: ZD1839, an epidermal growth factor tyrosine kinase inhibitor is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer. Ann Oncol 2002;13(suppl 5):3270a.
69. Soulié P, Trump D, Wilding G, et al: ZD1839, an epidermal growth factor tyrosine kinase inhibitor in combination with docetaxel and estramustine in patients with hormone refractory prostate cancer. Ann Oncol 2002;13(suppl 5):3280a.
70. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI: HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94:980-986.
71. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol 2001;4(suppl 15):71-76.
72. Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997;89:182-185.
73. Joly F, Tannock IF: Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol 2004;15:1582-1584.
74. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA Jr: Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005;103:11-21.
75. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R: Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147-8151.
76. Shulman MJ, Benaim EA: The natural history of androgen independent prostate cancer. J Urol 2004;172:141-145.
77. Diaz M, Patterson SG: Management of androgen-independent prostate cancer. Cancer Control 2004;11:364-373.